-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14

Benzinga·11/09/2026 13:41:53
Listen to the news
RBC Capital analyst Douglas Miehm initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $14.